Ondine Biomedical Inc Deploys Steriwave Across British Columbia Health Authorities

Ondine Biomedical Inc. (LON:OBI) has announced that its Steriwave® nasal decolonization technology is now used across all five health authorities of British Columbia. This rollout emphasizes the growing presence of Ondine in Canadian healthcare.

As of August 21, 2024, the University Hospital of Northern British Columbia (UHNBC) started using Steriwave for patients undergoing hip and knee surgeries. This marks the technology's implementation in Vancouver Coastal Health, Fraser Health, Vancouver Island Health, Interior Health, and Northern Health.

CEO Carolyn Cross stated that Steriwave's non-resistance-forming photodisinfection underlines their effort to combat multidrug resistance and other health threats. She highlighted the technology's impact on reducing hospital-acquired infections.

Hospitals using Steriwave have reported fewer surgical site infections, reduced antibiotic use, shorter hospital stays, and significant cost savings with high compliance and satisfaction levels.

Steriwave is a non-invasive, light-activated antimicrobial treatment that significantly reduces nasal pathogens. This technology is effective against both moderately and extensively drug-resistant pathogens, providing an alternative to antibiotics.